These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23456099)

  • 1. One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.
    Ohkuma Y; Hayashi T; Sakai T; Watanabe A; Tsuneoka H
    Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):1909-17. PubMed ID: 23456099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy with good baseline visual acuity.
    Hayashida M; Miki A; Nakai S; Matsumiya W; Imai H; Kusuhara S; Nakamura M
    PLoS One; 2020; 15(10):e0240557. PubMed ID: 33044997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
    Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
    Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term outer retinal changes in central serous chorioretinopathy submitted to half-dose photodynamic therapy.
    Torres-Costa S; Penas S; Cerqueira AR; Brandão E; Carneiro Â; Rocha-Sousa A; Falcão-Reis F
    Photodiagnosis Photodyn Ther; 2021 Jun; 34():102235. PubMed ID: 33631379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.
    Vasconcelos H; Marques I; Santos AR; Melo P; Pires I; Figueira J; de Abreu JF; Cachulo ML; Silva R
    Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1697-705. PubMed ID: 23389551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Gulkas S; Sahin O
    Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
    Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Moussa S; Glittenberg C; Krebs I; Binder S
    Retina; 2012; 32(10):2014-9. PubMed ID: 22466482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
    Arevalo JF; Espinoza JV
    Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
    Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
    Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
    Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy.
    Altinel MG; Kanra AY; Totuk OMG; Ardagil A; Kabadayi K
    Photodiagnosis Photodyn Ther; 2021 Mar; 33():102081. PubMed ID: 33157327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinal thickness changes following photodynamic therapy in chronic central serous chorioretinopathy.
    Copete S; Ruiz-Moreno JM; Cava C; Montero JA
    Graefes Arch Clin Exp Ophthalmol; 2012 Jun; 250(6):803-8. PubMed ID: 22222922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy for chronic central serous chorioretinopathy.
    Ruiz-Moreno JM; Lugo FL; Armadá F; Silva R; Montero JA; Arevalo JF; Arias L; Gómez-Ulla F
    Acta Ophthalmol; 2010 May; 88(3):371-6. PubMed ID: 19958296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.